EFFICACY AND TOLERABILITY OF BRODIMOPRIM AT 2 DIFFERENT DOSAGE SCHEDULES IN THE TREATMENT OF ACUTE UNCOMPLICATED BACTERIAL CYSTITIS - COMPARATIVE-STUDY VS PEFLOXACIN

In an open study, 172 male and female adult patients with acute uncomp licated bacterial cystitis were randomly allocated to three treatment groups. Two groups received brodimoprim 200 mg tablets as follows: a s ingle dose of two 200 mg tablets on day 1, followed by one tablet per day on days 2 and 3 (58 patients); or a single daily dose of two table ts, for 2 days (63 patients). The third group received a single dose o f pefloxacin, as two 400 mg tablets, for 1 day (51 patients). Complete urinalysis, sediment and urine culture examinations were carried out before treatment and 10 days after the last dose. Evaluation also comp rised, at the time of enrolment and 48 h after the last dose, measurem ent of corporal temperature and assessment of symptoms (dysuria, polla kiuria, strangury, suprapubic pain, burning sensation during urination and urgency) on a 4-point scale. The eradication rate for the pathoge n concerned was 98.3% and 96.7% in the groups receiving brodimoprim fo r 3 and 2 days, respectively, and 92.8% in the pefloxacin group (betwe en-group comparison n.s.). There was significant regression of symptom s (P < 0.001) in the three groups (between-groups comparison n.s.). Ma inly gastrointestinal adverse events occurred in 3 patients receiving brodimoprim for 2 days and in 4 patients from each of the other two gr oups.